arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Immunome Inc.

IMNM
$25.01 ▼ -0.86 (-3.32%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
29 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

Immunome Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.8B
Dividend Yield
Revenue Growth N/M
Op. Margin None
ROIC -8.0%
FCF / Share $-0.54
Trailing P/E
Price / Book 4.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

29-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-53.84M
↓ -29.3%
Operating Margin Operating profit as % of sales
-130.0%
↑ +4.0%
FCF / Share Free cash flow per share
$-0.54
↑ +23.7%
Long-Term Debt Long-term obligations
$500.00K
↑ +273.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
22
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 29 quarters